Core Points - Rosen Law Firm is reminding purchasers of Inspire Medical Systems, Inc. common stock about the lead plaintiff deadline of January 5, 2026, for a class action lawsuit [1] - Investors who purchased stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the firm [3] Company Details - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and necessary steps for its launch, leading to investor damages when the truth was revealed [5] - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, of the December 29, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [2][5] - A lead plaintiff is a representative party who directs the litigation on behalf of other class members, and a motion must be filed by December 29, 2025, to serve in this role [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3] Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [4] - It is claimed that the enhancements to the G7 were overstated, and the true scope of the issues was downplayed, leading to increased regulatory scrutiny and potential legal repercussions for DexCom [4] - The public statements made by DexCom during the Class Period are alleged to have been materially false and misleading, resulting in investor damages when the truth was revealed [4]

Core Insights - DexCom, Inc. (NASDAQ:DXCM) is facing challenges due to broader weakness in the medical devices industry and increased scrutiny from the FDA and customers regarding product reliability [2] - Despite these pressures, DexCom has shown strong operational execution, with three consecutive quarters of accelerating year-over-year revenue growth and near-record new patient additions [2] - The company raised its 2025 revenue guidance, but the increase was more cautious than market expectations, leading to disappointment among investors [2] - DexCom's stock is trading near its all-time low forward earnings multiple, indicating a potential disconnect from its growth outlook [2] - Potential catalysts for DexCom include strong adoption of its newly launched 15-day sensor, expanded Medicare coverage for type-2 non-insulin patients, and clarity on the company's long-range plan [2] - The 15-day sensor is expected to contribute significantly to profitability in 2026 through margin leverage [2] Market Sentiment - Jim Cramer expressed concerns about the stock being "too rich" and highlighted the potential impact of GLP-1 medications on DexCom's market [1] - There is a belief that certain AI stocks may offer greater upside potential compared to DexCom, despite acknowledging its investment potential [2]

Core Viewpoint - Integer Holdings Corporation is facing a class action lawsuit for allegedly misleading investors regarding its competitive position and sales performance in the electrophysiology market, leading to significant stock price declines [1][3][4]. Summary by Sections Class Action Lawsuit Details - The lawsuit is titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation and covers purchasers of Integer Holdings common stock from July 25, 2024, to October 22, 2025 [1]. - Investors have until February 9, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. Allegations Against Integer Holdings - The lawsuit claims that Integer Holdings overstated its competitive position in the electrophysiology manufacturing market [3]. - It alleges that despite claims of strong customer demand visibility, the company was experiencing a decline in sales for two of its electrophysiology devices [3]. - Integer Holdings mischaracterized its electrophysiology devices as long-term growth drivers for its Cardio & Vascular segment [3]. Financial Performance and Stock Impact - On October 23, 2025, Integer Holdings lowered its full-year 2025 sales guidance, which was below analysts' expectations [4]. - The company projected net sales growth of -2% to 2% and organic sales growth of 0% to 4% for the full year of 2026 [4]. - Following this announcement, the stock price of Integer Holdings fell by more than 32% [4]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased stock during the class period to seek lead plaintiff status [5]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [5]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases [6].

Core Points - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered systemic defects leading to serious patient risks [3][7] - The lawsuit covers individuals who purchased Baxter common stock between February 23, 2022, and October 29, 2025, with a deadline of December 15, 2025, for investors to apply as lead plaintiffs [7] Allegation Details - The complaint claims that Baxter failed to disclose critical information about the Novum LVP, including systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, which posed risks of serious injury or death to patients [3] - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures, leading to continued harm [3] - The lawsuit suggests that Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were materially false and misleading [3] Next Steps - Investors who suffered losses and wish to learn more about the claims or have questions are encouraged to contact the law firm Bragar Eagel & Squire, P.C. for further information [4] - The firm emphasizes that there is no cost or obligation for investors to inquire about their rights [4] About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in complex litigation across state and federal courts [5]

Core Points - Class actions have been initiated on behalf of stockholders of Stride, Inc. and Inspire Medical Systems, Inc. with deadlines for lead plaintiff petitions approaching [1] Stride, Inc. (NYSE:LRN) - The class period for Stride, Inc. is from October 22, 2024, to October 28, 2025, with a lead plaintiff deadline of January 12, 2026 [5] - Allegations against Stride include inflating enrollment numbers, cutting staffing costs, ignoring compliance requirements, suppressing whistleblowers, and losing enrollments, leading to artificially inflated stock prices [5] Inspire Medical Systems, Inc. (NYSE:INSP) - The class period for Inspire Medical is from August 6, 2024, to August 4, 2025, with a lead plaintiff deadline of January 5, 2026 [5] - The lawsuit claims that the launch of Inspire V was unsuccessful due to poor demand and undisclosed challenges, resulting in a more than 80% reduction in 2025 earnings guidance and a stock price decline of over 32% [5]

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to significant delays in adoption [5][6]. - The company faced weak demand for Inspire V as many customers had excess inventory of older devices [6]. Stock Performance and Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 to $87.91 between August 4 and August 5, 2025 [8].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and certain senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Impact - On October 23, 2025, Integer revised its 2025 sales guidance downward to between $1.840 billion and $1.854 billion, significantly below analysts' expectations. The company also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, over 32%, from $109.11 to $73.89 [6].

Core Viewpoint - Baxter International, Inc. is facing a securities fraud class action lawsuit due to serious safety issues related to its Novum IQ Large Volume Pump, which has been linked to patient injuries and deaths, leading to a significant drop in stock price [1][4][5]. Group 1: Incident Overview - On April 7, 2025, a Missouri news outlet reported safety issues with Baxter's Novum LVP, claiming it was unsafe for patient treatment based on a whistleblower's information [2]. - Baxter issued warning letters on April 24 and July 14, 2025, regarding underinfusion and overinfusion risks, revealing 79 reports of serious injuries and two patient deaths associated with the device [3]. - The FDA classified the issues with Novum LVP as a Class I recall, indicating a severe risk of injury or death [3]. Group 2: Stock Impact - Following the announcement of a voluntary pause in shipments and installations of the Novum LVP on July 31, 2025, Baxter's stock price fell by $6.24, or 22.4%, closing at $21.61 per share [4]. Group 3: Lawsuit Details - The lawsuit alleges that Baxter made false or misleading statements regarding the safety and functionality of the Novum LVP, failing to disclose systemic defects and the risks associated with the device [5]. - It is claimed that Baxter was aware of multiple malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of customers removing the devices from service [5].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to significant operational issues and a drastic reduction in earnings guidance following the announcement of delays in the launch of its new sleep apnea device, Inspire V [2][4]. Company Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V was delayed due to multiple issues, including inadequate training and onboarding of treatment centers, software update delays, and excess inventory leading to poor demand [2]. - The company reduced its 2025 earnings guidance by over 80%, from a range of $2.20 to $2.30 per share to a new range of $0.40 to $0.50 per share [2]. Stock Market Reaction - Following the announcement on August 5, 2025, Inspire's stock price dropped by $42.04, or 32.4%, closing at $87.91 per share, resulting in significant losses for investors [3]. Legal Allegations - The class action complaint alleges that during the class period, the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and operations [4]. - Specific allegations include poor demand for Inspire V due to surplus inventory, incomplete training for treatment centers, and failure to ensure necessary IT systems and Medicare reimbursement were in place at launch [4].